Coleman Mark sold $1.2M of AXSM
Coleman Mark sold 5,537 shares of Axsome Therapeutics, Inc. (AXSM) at $223.39 ($1.24M total) on 2026-06-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The key new datapoint is the director’s open-market sale amount and the confirmation that it was executed under a pre-arranged 10b5-1 plan.
Market read
This is a sentiment/positioning input rather than a fundamental catalyst; expected impact is modest.
What to watch
Traders may overreact to insider selling without checking whether it’s part of a scheduled plan and without comparing to prior insider activity levels.
Background
The article is an SEC Form 4 disclosure of an insider transaction for Axsome Therapeutics (AXSM).
Ticker impact
Axsome Therapeutics director Coleman Mark sold $1.24M of AXSM shares in an open-market transaction filed June 2.
Likely limited near-term impact; any reaction should be small unless accompanied by other company-specific catalysts.
Form 4 insider sales can move sentiment, but 10b5-1 pre-arranged plans typically reflect scheduled liquidity rather than new negative information.
Market effects
Minimal; this is company-specific insider liquidity rather than a sector/regulatory/drug-trial update.
None.
None.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may be routine and not predictive of fundamentals.
Key entities
- issuerAxsome Therapeutics, Inc.
Public company whose director sold shares via an open-market transaction under a 10b5-1 plan.
- insiderColeman Mark
Director who sold 5,537 AXSM shares for ~$1.24M.
